Biologics News
FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson
CARY, N.C., Dec. 20, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was
OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson
CARY, N.C., Dec.5, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by SpringWorks
TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Dec.1, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by AstraZeneca
FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 15, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by
OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson
CARY, N.C., Sept. 20, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by
VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Aug. 4, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was